Novel treatment strategies for EGFR mutant lung cancer

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard of care for patients with advanced EGFR mutant non-small cell lung cancer (NSCLC). Osimertinib, a mutant selective EGFR TKI, when used as initial therapy, results in median progression free survival (PFS) of 18.9 months. However, all patients ultimately develop resistance to osimertinib and new strategies to enhance the initial efficacy of osimertinib or...